4502: Takeda Pharmaceutical Company Limited - Summary | Jitta

Takeda Pharmaceutical Company Limited

TYO:4502

Price
¥3,133.00
Loss Chance
42.5%
4.90JITTA SCORE
31.27%Under Jitta Line
Jitta Ranking
163 / 3,451
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (56)
Recent Business Performance (66)
Financial Strength (59)
Return to Shareholders (1)
Competitive Advantage (50)
Jitta Signs
SG&A to SalesDecreasing Every Year
Revenue and EarningRevenue decline from 2018-2021
Debt LevelVery High Long Term Debt
Recent Business PerformanceEarning decline 13.98% in the last year
New Share IssuedMore than 50% in 5 years
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
4.90
31.27%
4.62
257.95%
4.52
231.60%
Pharmaceuticals
5.63
35.60%
7.03
233.07%
7.98
6.82%
COMPANY DESCRIPTION
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.